Gradientech signs exclusive contract with UK distributor
The diagnostic company Gradientech today announces an exclusive distribution agreement with AB Scientific for the commercialisation of QuickMIC® in United Kingdom and Ireland.
AB Scientific is a supplier of exclusive innovative products for all area of pathology from selected leading manufacturers across the world.
“AB Scientific are at the forefront of improving diagnostics in the UK and Ireland with innovative and high-quality products, and the addition of the QuickMIC product line from Gradientech supports our mission. We have been focused on improvements to the Sepsis Pathway for several years and by introducing the QuickMIC technology to the UK and Irish market we enable even faster turnaround times, reduced healthcare costs, and ultimately more saved lives. Our customers are at the forefront of everything they do, and the QuickMIC solution will allow them to make a real difference to their patients’ lives”, comments Greg Dobson, Director at AB Scientific.
Gradientech already has exclusive distribution agreements for the commercialisation of QuickMIC with Biomedica in Austria and Central Eastern Europe, with the Triolab group in Sweden, Denmark, Norway, Iceland, Finland and the Baltics and with Iberlab in Portugal.
“We are very proud to present AB Scientific as our exclusive distributor in UK and Irland with their solid experience, great expertise and the muscles needed to successfully roll-out QuickMIC on this significant European market. AB Scientific has an excellent track record having introduced new diagnostic systems from both Genmark Diagnostics and Accelerate Diagnostics to the UK clinical microbiology market and we are very excited about their trust in Gradientech and QuickMIC”, says Peter Karlberg, VP Sales at Gradientech.
Visit www.abscientific.com for more information about AB Scientific and their product lines.
For further information, please contact:
Peter Karlberg, VP Sales Gradientech
Tel: + 46 763 29 08 14
peter.karlberg@gradientech.se
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se
About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.
